CareRx valuation- IA Capital Markets- May 19- $10.75 Valuation
April was an extremely active month for CRRX with not one, but three accretive
acquisitions. The acquisitions propelled CRRX to reach ~92,000 beds serviced, which
we believe will increase with at least another 8,000 beds in organic growth in 2021.
Increased revenue, coupled with cost-saving synergies and an increased competitive
advantage with favourable drug pricing and an improved competitive landscape,
allow us remain bullish on CRRX in 2021. We value CareRx using the average of DCF,
EV/EBITDA and EV/Revenue valuations to arrive at our $10.75/share target price
(previously $7.50/share). We reiterate our Buy recommendation.